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PCLINICAL RESEARCH Valvular Heart Disease
Effect of Beta-Blocker Therapy on Survival
in Patients With Severe Aortic Regurgitation
Results From a Cohort of 756 Patients
Unnati Sampat, MD, Padmini Varadarajan, MD, Rami Turk, MD, Ashvin Kamath, BA,
Sumit Khandhar, DO, Ramdas G. Pai, MD
Loma Linda, California
Objectives We sought to investigate the effect of beta-blocker (BB) therapy on survival in patients with severe aortic regurgi-
tation (AR).
Background Beta-blockers are thought to be contraindicated in patients with AR because a slower heart rate increases the
duration of diastole during which AR occurs. But AR also causes neuroendocrine activation similar to a heart
failure state for which BBs are potentially beneficial.
Methods This is an observational study. Our echocardiographic database was screened for patients with severe AR. De-
tailed chart reviews were performed for clinical, demographic, and therapeutic data. Mortality data were ob-
tained from the Social Security Death Index and analyzed as a function of BB therapy.
Results Three hundred fifty-five (47%) of the 756 patients with severe AR were on a BB; mean age 61  18 years
and ejection fraction was 54  19%. Over a mean follow-up of 4.5 years, BB therapy was associated with a
higher survival rate (1- and 5-year survival rates of 90% and 70%, respectively) compared with those with-
out (1- and 5-year survival rates of 75% and 55%, respectively) (p  0.0009). The Cox regression model
showed that BB therapy was an independent predictor of better survival after adjusting for age, sex, heart
rate, hypertension, coronary artery disease, diabetes mellitus, heart failure, renal insufficiency, ejection
fraction, and aortic valve replacement (hazard ratio: 0.74, 95% confidence interval: 0.58 to 0.93, p  0.01).
The survival benefit of BB therapy was further supported by propensity score analysis.
Conclusions This observational study strongly suggests that BB therapy is associated with a survival benefit in patients with
severe AR. (J Am Coll Cardiol 2009;54:452–7) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.02.077M
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gortic regurgitation (AR) represents a condition of com-
ined volume and pressure overload (1). Volume overload
mposed by aortic regurgitation (AR) results in neuroendo-
rine activation, including a heightened beta-adrenergic
tate, reduced myocyte protein synthesis, and extracellular
atrix (ECM) degradation similar to a heart failure state
1–3). Beta-blockade in patients with heart failure decreases
roinflammatory cytokines and is associated with increased
urvival (4–8). Animal studies of chronic AR have shown a
rotective effect of beta-blockers (BBs) against development
f myocardial dysfunction (9,10) and for improved survival.
e investigated the potential survival benefit of BB therapy
n a large cohort of patients with severe AR.
rom the Division of Cardiology, Loma Linda University Medical Center, Loma
inda, California.p
Manuscript received December 14, 2008; revised manuscript received February 13,
009, accepted February 24, 2009.ethods
atient selection. This was a retrospective observational
tudy conducted in a large university medical center. The
tudy was approved by the institutional review board, which
aived the need for patient consent. The echocardiographic
atabase was searched for patients with severe AR during
he period from 1993 to 2007. Severe AR was diagnosed
See page 458
ased on 1 or more criteria, including jet height to left
entricular (LV) outflow tract diameter of 60% or prominent
olodiastolic flow reversal in the aortic arch or abdominal aorta
s judged by a Level 3-trained echocardiographer (11). This
ielded a total of 786 patients. Complete clinical, echocardio-
raphic, and pharmacological data were compiled on these
atients from comprehensive chart review. Thirty of the 786
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July 28, 2009:452–7 Beta-Blockers in Severe ARatients, who did not have any follow-up, were excluded from
he study. The remaining 756 patients formed the study
ohort.
linical variables. Various clinical comorbidities were de-
ned as follows: Hypertension was defined as a blood
ressure 130/90 mm Hg, being on any antihypertensive
edication, or a documented history of hypertension. Dia-
etes mellitus was defined as a fasting blood sugar of 126
g/dl or being on treatment for diabetes. Renal insuffi-
iency was defined as a creatinine value2 mg/dl. Coronary
rtery disease (CAD) was defined as the presence of 1 of
he following: a documented history of myocardial infarc-
ion or CAD, a positive stress test, angiographic evidence of
AD with lesions 50%, or a history of coronary interven-
ion or coronary artery bypass grafting, or the presence of
ignificant Q waves on the electrocardiogram.
chocardiography. All patients had standard 2-dimensional
chocardiographic examinations. The LV ejection fraction
EF) was assessed visually by a Level 3-trained echocardi-
grapher and entered into a database at the time of the
xamination. This has been proven to be reliable and has
een validated against contrast and radionuclide LV
ngiography (12,13). Anatomic and Doppler examina-
ions and measurements were performed according to the
ecommendations of the American Society of Echocar-
iography (14).
harmacological data. Pharmacotherapy around the time
f initial echo was recorded and placed into broad categories
f BBs, calcium-channel blockers, angiotensin-converting
nzyme (ACE) inhibitors, diuretic agents, antiarrhythmic
gents, digoxin, aspirin, and statins. Patients were consid-
red to be on a pharmacological agent only if they received
t for at least 1 month’s duration. However, most of the
atients continued on the BB and other medications for the
ength of the recorded clinical observation.
ortality data. The end point of the study was all-cause
ortality. Mortality data were obtained from the National
eath Index using social security numbers. Mortality was
ssessed and patient follow-up was censored in August
007.
tatistical methods. Stat View version 5.01 (SAS Insti-
ute, Cary, North Carolina) program was used for statistical
nalysis. Kaplan-Meier survival curves were computed for
atients with severe AR with and without BBs and were
ompared using the log-rank statistic. Characteristics of
atients with and without BB therapy were compared using
he Student t test for continuous variables and the chi-
quare test for categorical variables. Cox proportional haz-
rds models and propensity score analysis were employed to
djust for comorbidities and covariate imbalances (15–17).
p value of 0.05 was considered significant.
esults
atient characteristics. A total of 756 patients had severe
R. Baseline characteristics of these patients were: meange 61  18 years, 59% men,
ean LVEF 54  19%, and
iabetes mellitus in 14%, hyper-
ension in 65%, and CAD in
3%. Of the entire cohort, 47%
ere on a BB, and 38% under-
ent aortic valve replacement
AVR) during follow-up. The
ikely causes of AR based on
chocardiographic appearance
nd chart review were as follows:
icuspid aortic valve in 78 (10%),
ilated aortic root in 79 (10%),
egenerative or calcific aortic
alve disease in 220 (30%), and prior infective endocarditis
n 78 (10%) patients. The rest of the patients had mixed or
nclear mechanisms.
omparison of patients with and without BB. Table 1
hows the comparison of patients with severe AR, with and
ithout BB therapy. Patients on BBs were younger (60 
7 years vs. 63  18 years, p  0.01) and had a higher
revalence of CAD (38% vs. 29%, p 0.007), hypertension
74% vs. 56%, p  0.0001), AVR (49% vs. 28%, p 
.0001), and concomitant ACE inhibitor therapy (52% vs.
0%, p  0.0005).
haracteristics of Aortic Regurgitationatients Wi h and Without Beta-BlockersTable 1 Characteristics of Aorti RegurgitationPatients With and Without Beta-Blockers
Variables
No Beta-Blocker
(n  401)
Beta-Blocker
(n  355) p Value
Age, yrs 63 18 60 17 0.01
Men 56% 63% 0.06
Coronary artery disease 29% 38% 0.007
Hypertension 56% 74% 0.0001
Diabetes mellitus 13% 15% 0.36
Renal insufficiency 20% 21% 0.67
Heart failure 68% 72% 0.19
Atrial fibrillation 27% 24% 0.27
Heart rate, beats/min 66 38 76 26 0.0001
Ejection fraction, % 54 19 54 18 0.68
Left ventricular end-diastolic
diameter, cm
5.6 1.1 5.8 1.0 0.05
Left ventricular end-systolic
diameter, cm
3.9 1.2 4.0 1.2 0.07
Ventricular septum, cm 1.2 0.26 1.3 0.25 0.001
Posterior wall, cm 1.1 0.24 1.2 0.21 0.002
Pulmonary artery systolic
pressure 60 mm Hg
18% 16% 0.54
Aspirin use 32% 47% 0.0001
Angiotensin-converting enzyme
inhibitor use
40% 53% 0.0005
Statin use 12% 30% 0.0001
Dihydropyridine calcium-
channel blocker use
16% 22% 0.03
Nondihydropyridine calcium-
channel blocker use
14% 13% 0.67
Aortic valve replacement 29% 49% 0.0001
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
AR  aortic regurgitation
AVR  aortic valve
replacement
BB  beta-blocker
CAD  coronary artery
disease
EF  ejection fraction
LV  left ventricularCoronary artery bypass grafting 13% 20% 0.005
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Beta-Blockers in Severe AR July 28, 2009:452–7ffect of BBs on survival. Over a period of 4.4  4.1
ears, there were a total of 321 deaths, 124 in the BB group
nd 197 in the no BB group. Figure 1 shows the effect of BB
herapy on survival in patients with severe AR using
aplan-Meier analysis and log rank statistic. Patients on
Bs (n  355) had a significantly higher survival of 90%
nd 70% at 1 and 5 years, respectively, compared with 75%
nd 55%, respectively, for patients without BB (n  401)
p  0.0009).
tratification by CAD status. To investigate whether the
B effect was through its anti-ischemic effect, we evaluated
B effect stratified by CAD status. In the CAD group (n 
53), there were 141 deaths (81 in the BB group and 60 in
he no BB groups); and in those without known CAD (n 
03), there were 180 deaths (63 in the BB group and 117 in
he no BB group). Figure 2 shows the effect of BBs on
urvival by CAD status. In patients without CAD, the 1-
nd 5-year survival rates with BBs were 90% and 75%,
espectively, compared to 75% and 62%, respectively, for
hose on no BB therapy (p 0.02). The p value adjusted for
ge, sex, and EF was 0.03. In patients with CAD, 1- and
-year survival rates with BB therapy were 85% and 65%,
espectively, compared with 72% and 45%, respectively, for
o BB therapy (p  0.0002), showing a mortality benefit
ndependent of CAD status. The adjusted p value of the
AD group was 0.002.
tratification based on hypertension. To eliminate the
ossibility that the effect of BB therapy is through blood
ressure reduction alone in hypertensive patients, we ana-
yzed those with and without hypertension separately. Of
he 487 patients with a history of hypertension, 263 were on
BB. There were 231 deaths (101 in those on BB therapy
nd 130 in those on no BB) in those with hypertension, and
0 (24 in those on a BB and 66 in those with no BB) in the
Figure 1 Kaplan-Meier Survival Curves of Patients
With Severe AR With and Without BB Therapy
AR  aortic regurgitation; BB  beta-blocker.69 patients without hypertension. Use of BBs was associ-ted with a significantly higher 1- and 5-year survival (88%
nd 68%, respectively) compared with 75% and 52% in those
ithout BB therapy (n  224) (p  0.0007) (Fig. 3A). The
value adjusted for age, sex, and EF was 0.02. In patients
ithout hypertension, 1- and 5-year survival rates with BBs
n  94) were 90% and 81%, respectively, compared with
8% and 68%, respectively, in those without BB therapy
n  175, p  0.03) (Fig. 3B), indicating a survival benefit
ndependent of hypertension status.
tratification based on heart rate. Of the 756 patients
ith severe AR, 657 had heart rate data recorded. The effect
f BBs on survival was analyzed in heart rate quartiles.
eta-blocker therapy was not associated with improved
urvival in the first and second quartiles (slower heart rates),
ut was associated with better survival in the third and
ourth quartiles (p  0.04 and p  0.001, respectively). In
ther words, benefit was seen in those with higher heart
ates.
ox regression models. Two types of Cox regression
odels were created to adjust for confounders. In the first,
Figure 2 Effect of BBs on Survival Stratified by CAD Status
Survival was better with beta-blockers (BBs) in
patients without (A) and with (B) coronary artery disease (CAD).
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July 28, 2009:452–7 Beta-Blockers in Severe ARhe effect of BB therapy on survival was assessed by
djusting for all group differences with p  0.10. Adjusted
ortality risk with BB therapy was 0.74 (95% confidence
nterval [CI]: 0.57 to 0.97, p  0.03). In the second model,
djustments were made for age, sex, heart rate, hyperten-
ion, CAD, diabetes, heart failure, renal insufficiency,
VEF, and aortic valve replacement. The mortality benefit
ssociated with BB therapy was unchanged (relative risk:
.74, 95% CI: 0.58 to 0.93, p  0.01).
ropensity score analysis. Propensity score analysis was
lso carried out to address the effect of covariate imbalance
etween the BB group and comparison group. The proba-
ility of receiving BBs (propensity score) for each patient
as modeled by using a logistic regression model condi-
ioned on covariate values for that individual. This has been
hown to reduce bias in observational studies (15–17).
eta-blocker therapy was an independent predictor of
urvival after adjusting for the propensity score using the
Figure 3 Effect of BBs on Survival
Stratified by Hypertension Status
Survival was better with beta-blockers (BBs)
in patients with (A) and without (B) hypertension.ox regression model (p  0.01). tnalysis censoring at the time of AVR. To analyze the
ffect of BB therapy on AR mortality alone rather than its
ffect after AVR, a separate analysis was performed by censor-
ng patients at the time of AVR. Kaplan-Meier analysis
howed that patients on BB therapy had a higher survival rate
s compared with those who were not on a BB (p  0.05).
iscussion
his observational study indicates that BB therapy may
enefit patients with severe AR irrespective of CAD and
ypertension status. The benefit is also predominantly seen
n those with faster heart rates, which may indicate higher
drenergic tone. Our observations are consistent with in
itro and animal data published by other investigators and
upport a hypothesis that elevated catecholamines are likely
o be detrimental in patients with severe AR, and blocking
heir effects could be beneficial.
yocardial changes produced by AR in humans. AR
auses LV remodeling, myocyte hypertrophy, degeneration,
nd apoptosis, an increase in intercellular collagen, and an
ncreased ECM. Volume overload from chronic AR leads to
series of compensatory mechanisms, including an increase
n end-diastolic volume and eccentric hypertrophy, followed
y an increase in LV afterload as evidenced by an increase in
ean systolic stress leading to further hypertrophy (18–21).
ventually, LV systolic dysfunction sets in, which is initially
eversible and later irreversible (19–21). Myocardial dys-
unction can be detected in asymptomatic patients with
evere AR and in patients with moderate to severe AR with
ormal LVEF using indices of LV contractile function
djusted for afterload (22). The LV long-axis function has
een shown to be abnormal in severe AR despite normal EF
23). Analysis of endomyocardial biopsies has shown that
egeneration of the cardiomyocytes is more prevalent in AR
ompared with aortic stenosis (24). As discussed later, many
f these deleterious processes are prevented by BBs.
ossible mechanisms of BB benefit in AR. In animal
odel AR, there is an increase in the level of circulating
atecholamines, myocardial fibrosis, and degeneration of
ardiac myocytes (24–26). Gupta et al. (27) have shown an
ncrease in fibronectin synthesis in cardiac fibroblast cultures
ubjected to simulated AR. Plante et al. (9) have studied the
ffectiveness of metoprolol in chronic AR in adult male
istar rats. They found that metoprolol treatment increases
he expression of beta1 adrenoceptor mRNA, reduces G
rotein receptor kinase 2 levels, and reduces the cross-
ectional area of cardiomyocytes, and it had a beneficial
ffect on ECM remodeling by inhibiting collagen and
bronectin expression. Subsequently, in a similar animal
tudy, they found that metoprolol improved 1-year survival,
inimized LV hypertrophy, improved LV filling pressures,
ecreased LV subendocardial fibrosis, and helped restore
he beta-adrenergic receptor ratio (10). Animal studies in
he context of heart failure have also shown that BBs
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Beta-Blockers in Severe AR July 28, 2009:452–7revent myocardial fibrosis even at doses that do not reduce
ystemic blood pressure (28,29).
Bs after AVR. Matuyama et al. (30) studied the effects of
B therapy in patients with normal EF after AVR for
hronic AR and found that the post-operative LV volume
nd LV mass index were significantly decreased in patients
ith BBs and concomitant ACE inhibitors compared with
CE inhibitors and no BBs. However, their sample size
as too small, and the effects of BB treatment were studied
nly after AVR.
evere AR and heart rate. It is generally believed that a
aster heart rate is beneficial in severe AR as it potentially
hortens the diastolic period during which AR occurs. But a
aster heart rate would also reduce left atrial emptying and
yocardial blood flow. A faster heart rate is also a reflection
f a higher level of circulating catecholamines, which are
otentially cardiotoxic. The ideal heart rate for hemody-
amics is unknown in human AR. In our study, the benefit
f BBs was seen in those with faster heart rates, perhaps
eflecting the benefit of BBs in those with a higher sympa-
hetic drive. It is also possible that the optimum target heart
ate in these individuals is perhaps in the range of 70 to 80
eats/min because a benefit of BB therapy was not seen in
hose with heart rates 70 beats/min. But it is more likely
hat the cellular and biochemical effects, rather than hemo-
ynamics, were more related to the survival benefit of BBs.
otential therapeutic mechanisms of BBs. Our study is
he first human study, to our knowledge, to show the
otential survival benefit of BB therapy in patients with
hronic severe AR. This was independent of the presence of
AD or hypertension, indicating that the benefit of BBs is
ikely due to mechanisms other than their antihypertensive
nd anti-ischemic properties. Selective benefit in those with
aster heart rates perhaps indicates that the mechanism may
e through blocking the actions of catecholamines resulting
n up-regulation of myocardial beta receptors. In addition,
Bs have an effect on metalloproteinases, which may result
n reduced LV remodeling and LV diastolic stiffness
28,29). BBs also reduce myocardial apoptotic rates and
educe myocyte hypertrophy (31). In addition, BBs have
ntiarrhythmic properties with a potential reduction in atrial
nd ventricular arrhythmias.
tudy limitations. This is a retrospective observational
tudy, and hence, treatment assignment is not random.
here were covariate imbalances between treatment and
ontrol groups. Adjustments for these were made using Cox
egression models and propensity score analysis. The latter
odel is reported to eliminate up to 90% of treatment bias
15–17), but a cause–effect relationship can not be con-
luded. We do not have comprehensive data on type, dose,
nd duration of BB therapy because of multiple formula-
ions and changing doses, making the intensity of exposure
ifficult to measure. However, we included only those
atients who received BBs for at least 1 month’s duration.
ost of the patients continued on the BB for the length ofhe recorded clinical observation. Only a randomized con-
1rolled trial can remove the bias and reliably measure
xposure to treatment.
onclusions
his retrospective observational study indicates that BB
herapy is associated with a better survival in patients with
evere AR. Prospective randomized controlled trials are
arranted to confirm these findings.
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